The U.S. Department of Health & Human Services (HHS) and the Food and Drug Administration (FDA) have initiated a new investigation into the safety of mifepristone, a drug approved 25 years ago for chemical abortions. The America First Policy Institute (AFPI) has expressed support for this move.
Dr. Jennifer Bauwens, Director of American Values at AFPI, praised the investigation, stating, "We commend HHS and the FDA for taking steps to review the safety of the abortion drug mifepristone, which is now used in roughly 60% of abortions in the U.S." She highlighted concerns about severe medical complications and mental health issues linked to the drug.
Hannah Anderson, director of Healthy America and senior director of Policy at AFPI, emphasized that Secretary Kennedy and Commissioner Makary are committed to ensuring health safety without yielding to ideological pressures. Anderson criticized claims that mifepristone is as safe as common pain relievers like Advil, pointing out observed dangerous complications.
Margo Nicholas, senior policy analyst for American Values at AFPI, expressed concern over the impact of mifepristone on both unborn children and women who take it. Nicholas said, "This drug is too dangerous to exist in the marketplace."
The full name of America First Policy Institute was mentioned in connection with their response to this investigation.
Information from this article can be found here.
